Chlamydia trachomatis (Trachoma, Genital Infections, Perinatal Infections, and Lymphogranuloma Venereum)

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

Volumn 2, Issue , 2014, Pages 2154.e1-2170.e6

  Batteiger, Byron E ^a   Tan, Ming ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adolescents; Biphasic developmental cycle; Cervicitis; Conjunctivitis; Endometritis; Epididymitis; Infertility; Nucleic acid amplification test (NAAT); Obligate intracellular bacterium; Pelvic inflammatory disease; Perihepatitis; Pharyngitis; Pneumonia; Proctitis; Reactive arthritis; Repeated infections; Salpingitis; Screening; Sexually transmitted infections; Urethritis

Indexed keywords

EID: 84944565705     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4801-3.00182-X     Document Type: Chapter

References (455)

1. Mariotti SP, Pascolini D, Rose-Nussbaumer J Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol 2009, 93:563-568.
2. Malhotra-Kumar S, Goossens H Editorial commentary: mass azithromycin distribution and emerging resistance: taking a minimum harm's approach. Clin Infect Dis 2013, 56:1527-1529.
3. Bhosai SJ, Bailey RL, Gaynor BD, Lietman TM Trachoma: an update on prevention, diagnosis, and treatment. Curr Opin Ophthalmol 2012, 23:288-295.
4. World Health Organization Global incidence and prevalence of selected curable sexually transmitted infections-2008 2012, World Health Organization, Geneva.
5. Centers for Disease Control and Prevention Sexually transmitted diseases surveillance 2011 2012, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.
6. Centers for Disease Control and Prevention Summary of notifiable diseases-United States, 2010. MMWR 2012, 59:1-110.
7. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among U.S. women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013, 40:187-193.
8. Datta SD, Torrone E, Kruszon-Moran D, et al. Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999-2008. Sex Transm Dis 2012, 39:92-96.
9. Centers for Disease Control and Prevention Sexually transmitted diseases surveillance, 2011 supplement: Chlamydia profiles, 2011 2012, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta.
10. Batteiger BE Chlamydia infection and epidemiology. Intracellular Pathogens I: Chlamydiales 2012, 1-26. ASM Press, Washington, DC. M. Tan, P.M. Bavoil (Eds.).
11. Moulder JW Interaction of chlamydiae and host cells in vitro. Microbiol Rev 1991, 55:143-190.
12. Stephens RS, Kalman S, Lammel C, et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 1998, 282:754-759.
13. Myers GSA, Crabtree J, Creasy HH Deep and wide: comparative genomics of Chlamydia. Intracellular Pathogens I: Chlamydiales 2012, 27-50. ASM Press, Washington, D.C. M. Tan, P.M. Bavoil (Eds.).
14. Palmer GH The highest priority: what microbial genomes are telling us about immunity. Vet Immunol Immunopathol 2002, 85:1-8.
15. Abdelrahman YM, Belland RJ The chlamydial developmental cycle. FEMS Microbiol Rev 2005, 29:949-959.
16. Rank RG, Whittimore J, Bowlin AK, Wyrick PB In vivo ultrastructural analysis of the intimate relationship between polymorphonuclear leukocytes and the chlamydial developmental cycle. Infect Immun 2011, 79:3291-3301.
17. Belland RJ, Zhong G, Crane DD, et al. Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A 2003, 100:8040-8042.
18. Shaw EI, Dooley CA, Fischer ER, et al. Three temporal classes of gene expression during the Chlamydia trachomatis developmental cycle. Mol Microbiol 2000, 37:913-925.
19. Saka HA, Thompson JW, Chen YS, et al. Quantitative proteomics reveals metabolic and pathogenic properties of Chlamydia trachomatis developmental forms. Mol Microbiol 2011, 82:1185-1203.
20. Saka HA, Valdivia RH Acquisition of nutrients by Chlamydiae: unique challenges of living in an intracellular compartment. Curr Opin Microbiol 2010, 13:4-10.
21. Newhall WJ Biosynthesis and disulfide cross-linking of outer membrane components during the growth cycle of Chlamydia trachomatis. Infect Immun 1987, 55:162-168.
22. Hatch TP Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in chlamydiae?. J Bacteriol 1996, 178:1-5.
23. Nelson DE The chlamydial cell envelope. Intracellular Pathogens I: Chlamydiales 2012, 74-96. ASM Press, Washington, D.C. M. Tan, P.M. Bavoil (Eds.).
24. Barry CE, Hayes SF, Hackstadt T Nucleoid condensation in Escherichia coli that express a chlamydial histone homolog. Science 1992, 256:377-379.
25. Wagar EA, Stephens RS Developmental form-specific DNA-binding proteins in Chlamydia spp. Infect Immun 1988, 56:1678-1684.
26. Brickman TJ, Barry CE, Hackstadt T Molecular cloning and expression of hctB encoding a strain-variant chlamydial histone-like protein with DNA-binding activity. J Bacteriol 1993, 175:4274-4281.
27. Omsland A, Sager J, Nair V, et al. Developmental stage-specific metabolic and transcriptional activity of Chlamydia trachomatis in an axenic medium. Proc Natl Acad Sci U S A 2012, 109:19781-19785.
28. Tipples G, McClarty G The obligate intracellular bacterium Chlamydia trachomatis is auxotrophic for three of the four ribonucleoside triphosphates. Mol Microbiol 1993, 8:1105-1114.
29. Fields KA Protein secretion and Chlamydia pathogenesis. Intracellular Pathogens I: Chlamydiales 2012, 192-216. ASM Press, Washington, DC. M. Tan, P.M. Bavoil (Eds.).
30. Hegemann JH, Moelleken K Chlamydial adhesion and adhesins. Intracellular Pathogens I: Chlamydiales 2012, 97-125. ASM Press, Washington, D.C. M. Tan, P.M. Bavoil (Eds.).
31. Zhang JP, Stephens RS Mechanism of Chlamydia trachomatis attachment to eukaryotic host cells. Cell 1992, 69:861-869.
32. Fadel S, Eley A Chlamydia trachomatis OmcB protein is a surface-exposed glycosaminoglycan-dependent adhesin. J Med Microbiol 2007, 56:15-22.
33. Moelleken K, Hegemann JH The Chlamydia outer membrane protein OmcB is required for adhesion and exhibits biovar-specific differences in glycosaminoglycan binding. Mol Microbiol 2008, 67:403-419.
34. Stephens RS, Koshiyama K, Lewis E, Kubo A Heparin-binding outer membrane protein of chlamydiae. Mol Microbiol 2001, 40:691-699.
35. Su H, Raymond L, Rockey DD, et al. A recombinant Chlamydia trachomatis major outer membrane protein binds to heparan sulfate receptors on epithelial cells. Proc Natl Acad Sci U S A 1996, 93:11143-11148.
36. Wehrl W, Brinkmann V, Jungblut PR, et al. From the inside out-processing of the chlamydial autotransporter pmpD and its role in bacterial adhesion and activation of human host cells. Mol Microbiol 2004, 51:319-334.
37. Ajonuma LC, Fok KL, Ho LS, et al. CFTR is required for cellular entry and internalization of Chlamydia trachomatis. Cell Biol Int 2010, 34:593-600.
38. Davis CH, Raulston JE, Wyrick PB Protein disulfide isomerase, a component of the estrogen receptor complex, is associated with Chlamydia trachomatis serovar E attached to human endometrial epithelial cells. Infect Immun 2002, 70:3413-3418.
39. Hall JV, Schell M, Dessus-Babus S, et al. The multifaceted role of oestrogen in enhancing Chlamydia trachomatis infection in polarized human endometrial epithelial cells. Cell Microbiol 2011, 13:1183-1199.
40. Kuo CC, Puolakkainen M, Lin TM, et al. Mannose-receptor positive and negative mouse macrophages differ in their susceptibility to infection by Chlamydia species. Microb Pathog 2002, 32:43-48.
41. Dautry-Varsat A, Subtil A, Hackstadt T Recent insights into the mechanisms of Chlamydia entry. Cell Microbiol 2005, 7:1714-1722.
42. Hackstadt T Initial interactions of chlamydiae with the host cell. Intracellular Pathogens I: Chlamydiales 2012, 126-148. ASM Press, Washington, DC. M. Tan, P.M. Bavoil (Eds.).
43. Byrne GI, Moulder JW Parasite-specified phagocytosis of Chlamydia psittaci and Chlamydia trachomatis by L and HeLa cells. Infect Immun 1978, 19:598-606.
44. Wyrick PB, Choong J, Davis CH, et al. Entry of genital Chlamydia trachomatis into polarized human epithelial cells. Infect Immun 1989, 57:2378-2389.
45. Hodinka RL, Davis CH, Choong J, et al. Ultrastructural study of endocytosis of Chlamydia trachomatis by McCoy cells. Infect Immun 1988, 56:1456-1463.
46. Hybiske K, Stephens RS Mechanisms of Chlamydia trachomatis entry into nonphagocytic cells. Infect Immun 2007, 75:3925-3934.
47. Clifton DR, Fields KA, Grieshaber SS, et al. A chlamydial type III translocated protein is tyrosine-phosphorylated at the site of entry and associated with recruitment of actin. Proc Natl Acad Sci U S A 2004, 10166-10171.
48. Carabeo RA, Grieshaber SS, Fischer E, Hackstadt T Chlamydia trachomatis induces remodeling of the actin cytoskeleton during attachment and entry into HeLa cells. Infect Immun 2002, 70:3793-3803.
49. Lane BJ, Mutchler C, Al Khodor S, et al. Chlamydial entry involves TARP binding of guanine nucleotide exchange factors. PLoS Pathog 2008, 4:e1000014.
50. Jewett TJ, Fischer ER, Mead DJ, et al. Chlamydial TARP is a bacterial nucleator of actin. Proc Natl Acad Sci U S A 2006, 103:15599-155604.
51. Jiwani S, Ohr RJ, Fischer ER, et al. Chlamydia trachomatis Tarp cooperates with the Arp2/3 complex to increase the rate of actin polymerization. Biochem Biophys Res Commun 2012, 420:816-821.
52. Clifton DR, Dooley CA, Grieshaber SS, et al. Tyrosine phosphorylation of the chlamydial effector protein Tarp is species specific and not required for recruitment of actin. Infect Immun 2005, 73:3860-3868.
53. Hower S, Wolf K, Fields KA Evidence that CT694 is a novel Chlamydia trachomatis T3S substrate capable of functioning during invasion or early cycle development. Mol Microbiol 2009, 72:1423-1437.
54. Abromaitis S, Stephens RS Attachment and entry of Chlamydia have distinct requirements for host protein disulfide isomerase. PLoS Pathog 2009, 5:e1000357.
55. Elwell CA, Ceesay A, Kim JH, et al. RNA interference screen identifies Abl kinase and PDGFR signaling in Chlamydia trachomatis entry. PLoS Pathog 2008, 4:e1000021.
56. Kim JH, Jiang S, Elwell CA, Engel JN Chlamydia trachomatis co-opts the FGF2 signaling pathway to enhance infection. PLoS Pathog 2011, 7:e1002285.
57. Rosmarin DM, Carette JE, Olive AJ, et al. Attachment of Chlamydia trachomatis L2 to host cells requires sulfation. Proc Natl Acad Sci U S A 2012, 109:10059-10064.
58. 31P nuclear magnetic resonance study of Chlamydia trachomatis: induction of ATPase activity in elementary bodies. Infect Immun 1989, 57:3338-3344.
59. Hatch TP, Miceli M, Sublett JE Synthesis of disulfide-bonded outer membrane proteins during the developmental cycle of Chlamydia psittaci and Chlamydia trachomatis. J Bacteriol 1986, 165:379-385.
60. Belland RJ, Zhong G, Crane DD, et al. Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A 2003, 100:8478-8483.
61. Lazarev VN, Borisenko GG, Shkarupeta MM, et al. The role of intracellular glutathione in the progression of Chlamydia trachomatis infection. Free Radic Biol Med 2010, 49:1947-1955.
62. Grieshaber NA, Sager JB, Dooley CA, et al. Regulation of the Chlamydia trachomatis histone H1-like protein Hc2 is IspE dependent and IhtA independent. J Bacteriol 2006, 188:5289-5292.
63. Grieschaber NA, Fischer ER, Mead DJ, et al. Chlamydial histone-DNA interactions are disrupted by a metabolite in the methylerythritol phosphate pathway of isoprenoid biosynthesis. Proc Natl Acad Sci U S A 2004, 101:7451-7456.
64. Grieshaber NA, Grieshaber SS, Fischer ER, et al. A small RNA inhibits translation of the histone-like protein Hc1 in Chlamydia trachomatis. Mol Microbiol 2006, 59:541-550.
65. Rosario CJ, Tan M The early gene product EUO is a transcriptional repressor that selectively regulates pro-moters of Chlamydia late genes. Mol Microbiol 2012, 84:1097-1107.
66. Brumell JH, Scidmore MA Manipulation of rab GTPase function by intracellular bacterial pathogens. Microbiol Mol Biol Rev 2007, 71:636-652.
67. Delevoye C, Nilges M, Dehoux P, et al. SNARE protein mimicry by an intracellular bacterium. PLoS Pathog 2008, 4:e1000022.
68. Kokes M, Valdivia RH Cell biology of the chlamydial inclusion. Intracellular Pathogens I: Chlamydiales 2012, 170-188. ASM Press, Washington, DC. M. Tan, P.M. Bavoil (Eds.).
69. Hackstadt T, Scidmore-Carlson MA, Shaw EI, Fischer ER The Chlamydia trachomatis IncA protein is required for homotypic vesicle fusion. Cell Microbiol 1999, 1:119-130.
70. Mital J, Miller NJ, Fischer ER, Hackstadt T Specific chlamydial inclusion membrane proteins associate with active Src family kinases in microdomains that interact with the host microtubule network. Cell Microbiol 2010, 12:1235-1249.
71. Niehus E, Cheng E, Tan M DNA supercoiling-dependent gene regulation in Chlamydia. J Bacteriol 2008, 190:6419-6427.
72. Tan M Temporal gene regulation during the chlamydial development cycle. Intracellular Pathogens I: Chlamydiales 2012, 149-169. ASM Press, Washington, DC. M. Tan, P.M. Bavoil (Eds.).
73. Clausen JD, Christiansen G, Holst HU, Birkelund S Chlamydia trachomatis utilizes the host cell microtubule network during early events of infection. Mol Microbiol 1997, 25:441-449.
74. Grieshaber SS, Grieshaber NA, Miller N, Hackstadt T Chlamydia trachomatis causes centrosomal defects resulting in chromosomal segregation abnormalities. Traffic 2006, 7:940-949.
75. Johnson KA, Tan M, Sutterlin C Centrosome abnormalities during a Chlamydia trachomatis infection are caused by dysregulation of the normal duplication pathway. Cell Microbiol 2009, 11:1064-1073.
76. Chen AL, Johnson KA, Lee JK, et al. CPAF: a chlamydial protease in search of an authentic substrate. PLoS Pathog 2012, 8:e1002842.
77. Elwell CA, Engel JN Lipid acquisition by intracellular chlamydiae. Cell Microbiol 2012, 14:1010-1018.
78. Newhall WJ Macromolecular and antigenic composition of chlamydiae. Microbiology of Chlamydia 1988, 48-70. CRC Press, Boca Raton, FL. A.L. Barron (Ed.).
79. Hackstadt T, Rockey D, Heinzen R, Scidmore M Chlamydia trachomatis interrupts an exocytic pathway to acquire endogenously synthesized sphingomyelin in transit from the Golgi apparatus to the plasma membrane. EMBO J 1996, 15:964-977.
80. Heuer D, Rejman Lipinski A, Machuy N, et al. Chlamydia causes fragmentation of the Golgi compartment to ensure reproduction. Nature 2009, 457:731-735.
81. Derre I, Swiss R, Agaisse H The lipid transfer protein CERT interacts with the Chlamydia inclusion protein IncD and participates to ER-Chlamydia inclusion membrane contact sites. PLoS Pathog 2012, 7:e1002092.
82. Elwell CA, Jiang S, Kim JH, et al. Chlamydia trachomatis co-opts GBF1 and CERT to acquire host sphingomyelin for distinct roles during intracellular development. PLoS Pathog 2011, 7:e1002198.
83. Cocchiaro JL, Kumar Y, Fischer ER, et al. Cytoplasmic lipid droplets are translocated into the lumen of the Chlamydia trachomatis parasitophorous vacuole. Proc Natl Acad Sci U S A 2008, 105:9379-9384.
84. Su H, McClarty G, Dong F, et al. Activation of Raf/MEK/ERK/cPLA2 signaling pathway is essential for chlamydial acquisition of host glycerophospholipids. J Biol Chem 2004, 279:9409-9416.
85. Yu HHY, Tan M Sigma 28 RNA polymerase regulates hctB, a late developmental gene in Chlamydia. Mol Microbiol 2003, 50:577-584.
86. Hybiske K, Stephens RS Mechanisms of host cell exit by the intracellular bacterium Chlamydia. Proc Natl Acad Sci U S A 2007, 104:11430-11435.
87. Beatty WL, Byrne GL, Morrison RP Morphologic and antigenic characterization of IFN-γ mediated persistent C. trachomatis infection in vitro. Proc Natl Acad Sci U S A 1993, 90:3998-4002.
88. Wyrick PB Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis 2010, 201(suppl 2):S88-S95.
89. Beatty WL, Belanger TA, Desai AA, et al. Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun 1994, 62:3705-3711.
90. Belland RJ, Nelson DE, Virok D, et al. Transcriptome analysis of chlamydial growth during IFN-gamma-mediated persistence and reactivation. Proc Natl Acad Sci U S A 2003, 100:15971-15976.
91. Klos A, Thalmann J, Peters J, et al. The transcript profile of persistent Chlamydophila (Chlamydia) pneumoniae in vitro depends on the means by which persistence is induced. FEMS Microbiol Lett 2009, 291:120-126.
92. Timms P, Good D, Wan C, et al. Differential transcriptional responses between the interferon-gamma-induction and iron-limitation models of persistence for Chlamydia pneumoniae. J Microbiol Immunol Infect 2009, 42:27-37.
93. Beatty WL, Morrison RP, Byrne GI Reactivation of persistent Chlamydia trachomatis infection in cell culture. Infect Immun 1995, 63:199.
94. Wang SP, Grayston JT Microimmunofluorescence antibody responses in Chlamydia trachomatis infection, a review. Chlamydial Infections 1982, 301-316. Elsevier Biomedical Press, Amsterdam. P.A. Mardh, K.K. Holmes, J.D. Oriel (Eds.).
95. Wang SP, Grayston JT Three new serovars of Chlamydia trachomatis: Da, Ia, and L2a. J Infect Dis 1991, 163:403-405.
96. Martin-Iguacel R, Llibre JM, Nielsen H, et al. Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialised countries. Eur J Clin Microbiol Infect Dis 2010, 29:917-925.
97. Batteiger Byron E, Tu W, Ofner S, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010, 201:42-51.
98. Stephens RS, Wagar EA, Schoolnik GK High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis. J Exp Med 1988, 167:817-831.
99. Batteiger BE The major outer membrane protein of a single Chlamydia trachomatis serovar can possess more than one serovar-specific epitope. Infect Immun 1996, 64:542-547.
100. Brade L, Nurminen M, Makela PH, Brade H Antigenic properties of Chlamydia trachomatis lipopolysaccharide. Infect Immun 1985, 48:569-572.
101. Belunis CJ, Mdluli KE, Raetz CRH, et al. A novel 3-deoxy-d-manno-octulosonic acid transferase from Chlamydia trachomatis required for expression of the genus-specific epitope. J Biol Chem 1992, 267:18702-18707.
102. Mondesire RR, Maclean IW, Shewen PE, et al. Identification of genus-specific epitopes on the outer membrane complexes of Chlamydia trachomatis and Chlamydia psittaci immunotypes 1 and 2. Infect Immun 1989, 57:2914-2918.
103. Yuan Y, Lyng K, Zhang YX, et al. Monoclonal antibodies define genus-specific, species-specific and cross-reactive epitopes of the chlamydial 60-kilodalton heat shock protein (hsp60): specific immunodetection and purification of chlamydial hsp60. Infect Immun 1992, 60:2288-2296.
104. Read TD, Brunham RC, Shen C, et al. Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Res 2000, 28:1397-1406.
105. Taylor LD, Nelson DE, Dorward DW, et al. Biological characterization of Chlamydia trachomatis plasticity zone MACPF domain family protein CT153. Infect Immun 2010, 78:2691-2699.
106. Nelson DE, Crane DD, Taylor LD, et al. Inhibition of chlamydiae by primary alcohols correlates with the strain-specific complement of plasticity zone phospholipase D genes. Infect Immun 2006, 74:73-80.
107. Seth-Smith HM, Thomson NR Whole-genome sequencing of bacterial sexually transmitted infections: implications for clinicians. Curr Opin Infect Dis 2013, 26:90-98.
108. Fehlner-Gardiner C, Roshick C, Carlson JH, et al. Molecular basis defining human C. trachomatis tissue tropism: a possible role for tryptophan synthase. J Biol Chem 2002, 13:468-476.
109. Caldwell HD, Wood H, Crane D, et al. Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J Clin Invest 2003, 111:1757-1769.
110. Carlson JH, Hughes S, Hogan D, et al. Polymorphisms in the Chlamydia trachomatis cytotoxin locus associated with ocular and genital isolates. Infect Immun 2004, 72:7063-7072.
111. Lutter EI, Bonner C, Holland MJ, et al. Phylogenetic analysis of Chlamydia trachomatis Tarp and correlation with clinical phenotype. Infect Immun 2010, 78:3678-3688.
112. Stothard DR, Toth GA, Batteiger BE Polymorphic membrane protein H has evolved in parallel with the three disease-causing groups of Chlamydia trachomatis. Infect Immun 2003, 71:1200-1208.
113. Gomes JP, Nunes A, Bruno WJ, et al. Polymorphisms in the nine polymorphic membrane proteins of Chlamydia trachomatis across all serovars: evidence for serovar Da recombination and correlation with tissue tropism. J Bacteriol 2006, 188:275-286.
114. Kari L, Whitmire WM, Carlson JH, et al. Pathogenic diversity among Chlamydia trachomatis ocular strains in nonhuman primates is affected by subtle genomic variations. J Infect Dis 2008, 197:449-456.
115. Somboonna N, Wan R, Ojcius DM, et al. Hypervirulent Chlamydia trachomatis clinical strain is a recombinant between lymphogranuloma venereum (L2) and D lineages. MBio 2011, 2:e00045-11.
116. Gomes JP, Bruno WJ, Nunes A, et al. Evolution of Chlamydia trachomatis diversity occurs by widespread interstrain recombination involving hotspots. Genome Res 2007, 17:50-60.
117. Harris SR, Clarke IN, Seth-Smith HM, et al. Whole-genome analysis of diverse Chlamydia trachomatis strains identifies phylogenetic relationships masked by current clinical typing. Nat Genet 2012, 44:413-419.
118. Brunelle BW, Sensabaugh GF The ompA gene in Chlamydia trachomatis differs in phylogeny and rate of evolution from other regions of the genome. Infect Immun 2006, 74:578-585.
119. Stothard DR, Boguslawski G, Jones RB Phylogenetic analysis of the Chlamydia trachomatis major outer membrane protein and examination of potential pathogenic determinants. Infect Immun 1998, 66:3618-3625.
120. Millman K, Black CM, Stamm WE, et al. Population-based genetic epidemiologic analysis of Chlamydia trachomatis serotypes and lack of association between ompA polymorphisms and clinical phenotypes. Microbes Infect 2006, 8:604-611.
121. Geisler WM, Suchland RJ, Whittington WL, Stamm WE The relationship of serovar to clinical manifestations of urogenital Chlamydia trachomatis infection. Sex Transm Dis 2003, 30:160-165.
122. Binet R, Maurelli AT Transformation and isolation of allelic exchange mutants of Chlamydia psittaci using recombinant DNA introduced by electroporation. Proc Natl Acad Sci U S A 2009, 106:292-297.
123. Wang Y, Kahane S, Cutcliffe LT, et al. Development of a transformation system for Chlamydia trachomatis: restoration of glycogen biosynthesis by acquisition of a plasmid shuttle vector. PLoS Pathog 2011, 7:e1002258.
124. Kari L, Goheen MM, Randall LB, et al. Generation of targeted Chlamydia trachomatis null mutants. Proc Natl Acad Sci U S A 2011, 108:7189-7193.
125. Demars R, Weinfurter J, Guex E, et al. Lateral gene transfer in vitro in the intracellular pathogen Chlamydia trachomatis. J Bacteriol 2007, 189:991-1003.
126. Nguyen BD, Valdivia RH Virulence determinants in the obligate intracellular pathogen Chlamydia trachomatis revealed by forward genetic approaches. Proc Natl Acad Sci U S A 2012, 109:1263-1268.
127. Kuo CC Host response. Microbiology of Chlamydia 1988, 193-208. CRC Press, Boca Raton, FL. A.L. Barron (Ed.).
128. Brunham RC, Paavonen J, Stevens CE, et al. Mucopurulent cervicitis: the ignored counterpart in women of urethritis in men. N Engl J Med 1984, 311:1-6.
129. Griffin M, Pushpanathan C, Andrews W Chlamydia trachomatis pneumonitis: a case study and literature review. Pediatr Pathol 1990, 10:843-852.
130. Braley AE Inclusion blennorrhea. Am J Ophthalmol 1938, 21:1203-1207.
131. Rasmussen SJ, Eckmann L, Quayle AJ, et al. Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest 1997, 99:77-87.
132. Ingalls RR, Rice PA, Qureshi N, et al. The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated. Infect Immun 1995, 63:3125-3130.
133. Darville T, Hiltke TJ Pathogenesis of genital tract disease due to Chlamydia trachomatis. J Infect Dis 2010, 201(suppl 2):S114-S125.
134. Darville T, O'Connell CM Chlamydia immunopathogenesis. Intracellular Pathogens I: Chlamydiales 2012, 240-264. ASM Press, Washington, D.C. M. Tan, P.M. Bavoil (Eds.).
135. Stephens RS The cellular paradigm of chlamydial pathogenesis. Trends Microbiol 2003, 11:44-51.
136. Buchholz KR, Stephens RS Activation of the host cell proinflammatory interleukin-8 response by Chlamydia trachomatis. Cell Microbiol 2006, 8:1768-1779.
137. Buchholz KR, Stephens RS The extracellular signal-regulated kinase/mitogen-activated protein kinase pathway induces the inflammatory factor interleukin-8 following Chlamydia trachomatis infection. Infect Immun 2007, 75:5924-5929.
138. Buchholz KR, Stephens RS The cytosolic pattern recognition receptor NOD1 induces inflammatory interleukin-8 during Chlamydia trachomatis infection. Infect Immun 2008, 76:3150-3155.
139. Rank RG In vivo chlamydial infection. Intracellular Pathogens I: Chlamydiales 2012, 285-310. ASM Press, Washington, D.C. M. Tan, P.M. Bavoil (Eds.).
140. Farris CM, Morrison RP Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model. Infect Immun 2011, 79:986-996.
141. Johnson RM Murine oviduct epithelial cell cytokine responses to Chlamydia muridarum infection include interleukin-12-p70 secretion. Infect Immun 2004, 72:3951-3960.
142. Derbigny WA, Kerr MS, Johnson RM Pattern recognition molecules activated by Chlamydia muridarum infection of cloned murine oviduct epithelial cell lines. J Immunol 2005, 175:6065-6075.
143. Derbigny WA, Hong SC, Kerr MS, et al. Chlamydia muridarum infection elicits a beta interferon response in murine oviduct epithelial cells dependent on interferon regulatory factor 3 and TRIF. Infect Immun 2007, 75:1280-1290.
144. Darville T, O'Neill JM, Andrews CW, et al. Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J Immunol 2003, 171:6187-6197.
145. Nagarajan UM, Prantner D, Sides JD, et al. Type I interferon signaling exacerbates Chlamydia muridarum genital infection in a murine model. Infect Immun 2008, 76:4642-4648.
146. Paavonen J, Kiviat N, Brunham RC, et al. Prevalence and manifestations of endometritis among women with cervicitis. Am J Obstet Gynecol 1985, 152:280-286.
147. Patton DL, Taylor HR The histopathology of experimental trachoma: ultrastructural changes in the conjunctival epithelium. J Infect Dis 1986, 153:870-878.
148. Patton DL, Kuo CC, Wang SP, et al. Distal tubal obstruction induced by repeated Chlamydia trachomatis salpingeal infections in pigtailed macaques. J Infect Dis 1987, 155:1292-1299.
149. Grayston JT, Wang SP, Yeh LJ, Kuo CC Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis 1985, 7:717-725.
150. Patton DL, Kuo CC, Wang SP, Halbert SA Distal tubal obstruction induced by repeated Chlamydia trachomatis salpingeal infections in pig-tailed macaques. J Infect Dis 1987, 155:1292-1299.
151. Taylor HR, Johnson SL, Prendergast RA, et al. An animal model of trachoma, II. The importance of repeated reinfection. Invest Ophthalmol Vis Sci 1982, 23:507-515.
152. Grayston JT, Wang SP, Lin HM, et al. Trachoma vaccine studies in volunteer students of the National Defense Medical Center, II. Response to challenge eye inoculation of egg grown trachoma virus. Chin Med J (Republic of China) 1961, 8:312-318.
153. Hu VH, Massae P, Weiss HA, et al. Bacterial infection in scarring trachoma. Invest Ophthalmol Vis Sci 2011, 52:2181-2186.
154. Peeling RW, Kimani J, Plummer F, et al. Antibody to chlamydial hsp60 predicts an increased risk for chlamydial pelvic inflammatory disease. J Infect Dis 1997, 175:1153-1158.
155. Peeling RW, Bailey RL, Conway DJ, et al. Antibody response to the 60-kDa chlamydial heat-shock protein is associated with scarring trachoma. J Infect Dis 1998, 177:256-259.
156. Zhong G, Peterson EM, Czarniecki CW, et al. Role of endogenous gamma interferon in host defense against Chlamydia trachomatis infections. Infect Immun 1989, 57:152-157.
157. Rothermel CD, Byrne GI, Havell EA Effect of interferon on the growth of Chlamydia trachomatis in mouse fibroblasts (L cells). Infect Immun 1983, 39:362-370.
158. Rank RG, Ramsey KH, Pack EA, et al. Effect of gamma interferon on resolution of murine chlamydial genital infection. Infect Immun 1992, 60:4427-4429.
159. Morre S, van den Brule AJC, Rozendaal L, et al. The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS 2002, 13(suppl 2):12-18.
160. Molano M, Meijer CJLM, Weiderpass E, et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis 2005, 191:907-916.
161. van den Brule AJC, Munk C, Winter JF, et al. Prevalence and persistence of asymptomatic Chlamydia trachomatis infections in urine specimens from Danish male military recruits. Int J STD AIDS 2002, 13(suppl 2):19-22.
162. Morrison RP New insights into a persistent problem-chlamydial infections. J Clin Invest 2003, 111:1647-1649.
163. Schachter J, Dawson CR Human Chlamydial Infections 1978, PSG Publishing, Littleton, MA.
164. Brunham RC, Kuo C, Chen WJ Systemic Chlamydia trachomatis infection in mice: a comparison of lymphogranuloma venereum and trachoma biovars. Infect Immun 1985, 48:78-82.
165. Li Z, Chen D, Zhong Y, et al. The chlamydial plasmid-encoded protein pgp3 is secreted into the cytosol of Chlamydia-infected cells. Infect Immun 2008, 76:3415-3428.
166. Donati M, Laroucau K, Storni E, et al. Serological response to pgp3 protein in animal and human chlamydial infections. Vet Microbiol 2009, 135:181-185.
167. Song L, Carlson JH, Whitmire WM, et al. Chlamydia trachomatis plasmid-encoded Pgp4 is a transcriptional regulator of virulence-associated genes. Infect Immun 2013, 81:636-644.
168. Carlson JH, Whitmire WM, Crane DD, et al. The Chlamydia trachomatis plasmid is a transcriptional regulator of chromosomal genes and a virulence factor. Infect Immun 2008, 76:2273-2283.
169. O'Connell CM, Ingalls RR, Andrews CW, et al. Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease. J Immunol 2007, 179:4027-4034.
170. Batteiger BE, Xu F, Johnson RE, Rekart ML Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. J Infect Dis 2010, 201:S178-S189.
171. Grayston JT, Wang SP, Yeh LJ, et al. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis 1985, 7:717-725.
172. Katz BP, Caine VA, Batteiger BE, et al. A randomized trial to compare 7- and 21-day tetracycline regimens in the prevention of recurrence of infection with Chlamydia trachomatis. Sex Transm Dis 1991, 18:36-40.
173. Blythe MJ, Katz BP, Batteiger BE, et al. Recurrent genitourinary chlamydial infections in sexually active female adolescents. J Pediatr 1992, 121:487-493.
174. Brunham RC, Kuo CC, Cles L, et al. Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix. Infect Immun 1983, 39:1491-1494.
175. Alani MD, Darougar S, Burns DC, et al. Isolation of Chlamydia trachomatis from the male urethra. Br J Vener Dis 1977, 53:88-92.
176. Cohen CR, Koochesfahani KM, Meier AS, et al. Immunoepidemiologic profile of Chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon gamma. Infect Immun 2005, 192:591-599.
177. Brunham RC, Pourbohloul B, Mak S, et al. The unexpected impact of a Chlamydia trachomatis infection control program on susceptiblity to reinfection. J Infect Dis 2005, 195:1836-1844.
178. Geisler WM, Lensing SY, Press CG, Hook EW Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection. J Infect Dis 2013, 207:1850-1856.
179. Igietseme JU, Ramsey KH, Magee DM, et al. Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, Th1 clone. Reg Immunol 1994, 5:317-324.
180. Su H, Feilzer K, Caldwell HD, et al. Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice. Infect Immun 1997, 65:1993-1999.
181. Morrison SG, Morrison RP A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J Immunol 2005, 175:7536-7542.
182. Cotter TW, Meng Q, Shen ZL, et al. Protective efficacy of major outer membrane protein specific immunoglobulin A (IgA) and IgG murine monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infect Immun 1995, 63:4704-4714.
183. Morrison SG, Morrison RP The protective effect of antibody in immunity to murine chlamydial genital tract reinfection is independent of immunoglobulin A. Infect Immun 2005, 73:6183-6186.
184. Igietseme JU, Black CM, Caldwell HD Chlamydia vaccines-strategies and status. Biodrugs 2002, 16:19-35.
185. Su H, Messer R, Whitmire W, et al. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable chlamydiae. J Exp Med 1998, 188:809-818.
186. Johnson RM, Kerr MS, Slaven JE Plac8-dependent and inducible NO synthase-dependent mechanisms clear Chlamydia muridarum infections from the genital tract. J Immunol 2012, 188:1896-1904.
187. Fung KY, Mangan NE, Cumming H, et al. Interferon-epsilon protects the female reproductive tract from viral and bacterial infection. Science 2013, 339:1088-1092.
188. Geisler WM Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies. J Infect Dis 2010, 201(suppl 2):S104-S113.
189. Zhong G, Fan P, Ji H, et al. Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J Exp Med 2001, 193:935-942.
190. de la Maza L, Peterson EM Vaccines for Chlamydia trachomatis infections. Curr Opin Investig Drugs 2002, 3:980-986.
191. Schautteet K, De Clercq E, Vanrompay D Chlamydia trachomatis vaccine research through the years. Infect Dis Obstet Gynecol 2011, 2011:963513.
192. Zhang D, Yang X, Berry J, et al. DNA vaccination with the major outer membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection. J Infect Dis 1997, 176:1035-1040.
193. Pal S, Barnhart KM, Wei Q, et al. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 1999, 17:459-465.
194. Pal S, Peterson EM, Rappuoli R, et al. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine 2006, 24:766-775.
195. Murthy AK, Guentzel MN, Zhong G, Arulanandam BP Chlamydial protease-like activity factor-insights into immunity and vaccine development. J Reprod Immunol 2009, 83:179-184.
196. Kari L, Whitmire WM, Olivares-Zavaleta N, et al. A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. J Exp Med 2011, 208:2217-2223.
197. Riley MM, Zurenski MA, Frazer LC, et al. The recall response induced by genital challenge with Chlamydia muridarum protects the oviduct from pathology but not from reinfection. Infect Immun 2012, 80:2194-2203.
198. Rockey DD Unraveling the basic biology and clinical significance of the chlamydial plasmid. J Exp Med 2011, 208:2159-2162.
199. Hu VH, Harding-Esch EM, Burton MJ, et al. Epidemiology and control of trachoma: systematic review. Trop Med Int Health 2010, 15:673-691.
200. Black CM Current methods of laboratory diagnosis of Chlamydia trachomatis infections. Clin Microbiol Rev 1997, 10:160-184.
201. Stamm WE Chlamydia trachomatis: the persistent pathogen: Thomas Parran Award Lecture. Sex Transm Dis 2001, 28:684-689.
202. Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010, 59:1-110.
203. Harkins AL, Munson E Molecular diagnosis of sexually transmitted Chlamydia trachomatis in the United States. ISRN Obstet Gynecol 2011, 2011:279149.
204. Gaydos CA, Ferrero DV, Papp J Laboratory aspects of screening men for Chlamydia trachomatis in the new millennium. Sex Transm Dis 2008, 35:S45-S50.
205. Schoeman SA, Stewart CM, Booth RA, et al. Assessment of best single sample for finding chlamydia in women with and without symptoms: a diagnostic test study. BMJ 2012, 345:e8013.
206. Schachter J, Chernesky MA, Willis DE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis 2005, 32:725-728.
207. Doshi JS, Power J, Allen E Acceptability of chlamydia screening using self-taken vaginal swabs. Int J STD AIDS 2008, 19:507-509.
208. Cook RL, Hutchison SL, Ostergaard L, et al. Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005, 142:914-925.
209. Chernesky M, Freund GG, Hook E, et al. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae infections in North American women by testing SurePath liquid-based Pap specimens in APTIMA assays. J Clin Microbiol 2007, 45:2434-2438.
210. Keenan JD, Ayele B, Gebre T, et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clin Infect Dis 2012, 54:253-256.
211. Bachmann LH, Johnson RE, Cheng H, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol 2010, 48:1827-1832.
212. Schachter J, Moncada J, Liska S, et al. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008, 35:637-642.
213. Hadgu A, Sternberg M Reproducibility and specificity concerns associated with nucleic acid amplification tests for detecting Chlamydia trachomatis. Eur J Clin Microbiol Infect Dis 2009, 28:9-15.
214. Morre SA, Ouburg S, van Agtmael MA, de Vries HJ Lymphogranuloma venereum diagnostics: from culture to real-time quadriplex polymerase chain reaction. Sex Transm Infect 2008, 84:252-253.
215. Dukers-Muijrers NH, Morre SA, Speksnijder A, et al. Chlamydia trachomatis test-of-cure cannot be based on a single highly sensitive laboratory test taken at least 3 weeks after treatment. PLoS One 2012, 7:e34108.
216. Pickett MA, Everson JS, Pead PJ, Clarke IN The plasmids of Chlamydia trachomatis and Chlamydophila pneumoniae (N16): accurate determination of copy number and the paradoxical effect of plasmid-curing agents. Microbiology 2005, 151:893-903.
217. Dille BJ, Butzen CC, Birkenmeyer LG Amplification of Chlamydia trachomatis by ligase chain reaction. J Clin Microbiol 1993, 31:729-731.
218. Unemo M, Clarke IN The Swedish new variant of Chlamydia trachomatis. Curr Opin Infect Dis 2011, 24:62-69.
219. Ripa T, Nilsson PA A Chlamydia trachomatis strain with a 377-bp deletion in the cryptic plasmid causing false-negative nucleic acid amplification test. Sex Transm Dis 2007, 34:255-256.
220. Persson K, Hammas B, Janson H, et al. Decline of the new Swedish variant of Chlamydia trachomatis after introduction of appropriate testing. Sex Transm Infect 2012, 88:451-455.
221. Won H, Ramachandran P, Steece R, et al. Is there evidence of the new variant Chlamydia trachomatis in the United States?. Sex Transm Dis 2013, 40:352-353.
222. Barnes RC, Katz BP, Rolfs RT, et al. Quantitative culture of endocervical Chlamydia trachomatis. J Clin Microbiol 1990, 28:774-780.
223. Stamm WE Diagnosis of Chlamydia trachomatis geni-tourinary infections. Ann Intern Med 1988, 108:710-717.
224. Scidmore MA Cultivation and laboratory maintenance of Chlamydia trachomatis. Curr Protoc Microbiol 2005.
225. Yoder BL, Stamm WE, Koester CM, et al. Microtest procedure for isolation of Chlamydia trachomatis. J Clin Microbiol 1981, 13:1036-1039.
226. Jones RB, Katz BP, Van Der Pol PB, et al. Effect of blind passage and multiple sampling on recovery of Chlamydia trachomatis from urogenital specimens. J Clin Microbiol 1986, 24:1029-1033.
227. Geisler WM, Suchland RJ, Whittington WLH, et al. Quantitative culture of Chlamydia trachomatis: relationship of inclusion-forming units produced in culture to clinical manifestations and acute inflammation in urogenital disease. J Infect Dis 2001, 184:1350-1354.
228. Schachter J, Dawson CR Human Chlamydial Infections 1978, PSG Publishing, Littleton, MA.
229. Dorman SA, Danos LM, Wilson DJ, et al. Detection of chlamydial cervicitis by Papanicolaou-stained smears and culture. Am J Clin Pathol 1983, 79:421-425.
230. Jain A, Ison CA Chlamydia point-of-care testing: where are we now?. Sex Transm Infect 2013, 89:88-89.
231. Gaydos CA, Van Der Pol B, Jett-Goheen M, et al. Performance of the Cepheid CT/NG Xpert rapid PCR test for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol 2013, 51:1666-1672.
232. Schachter J Chlamydiae. Manual of Clinical Immunology 1980, 700-706. American Society for Microbiology, Washington, DC. 2nd ed. N.R. Rose, H. Friedman (Eds.).
233. Geisler WM, Morrison SG, Doemland ML, et al. Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection. J Infect Dis 2012, 206:1836-1843.
234. Burton MJ, Mabey DCW The global burden of trachoma: a review. PLoS Negl Trop Dis 2009, 3:e460.
235. Frick KD, Hanson CL, Jacobson GA Global burden of trachoma and economics of the disease. Am J Trop Med Hyg 2003, 69:1-10.
236. West S Trachoma and antibiotic use: the 'A' in SAFE. Expert Rev Anti Infect Ther 2012, 10:75-83.
237. Schachter J, Dawson CR Human Chlamydial Infections 1978, PSG Publishing, Littleton, MA.
238. Dawson CR, Schachter J TRIC agent infections of the eye and genital tract. Am J Ophthalmol 1967, 63(suppl):1288-1298.
239. Stenson S Adult inclusion conjunctivitis: clinical characteristics and corneal changes. Arch Ophthalmol 1981, 99:605-608.
240. Rönnerstam R, Persson K, Hansson H, et al. Prevalence of chlamydial eye infection in patients attending an eye clinic, a VD clinic, and in healthy persons. Br J Ophthalmol 1985, 69:385-388.
241. Stenberg K, Mardh PA Genital infection with Chlamydia trachomatis in patients with chlamydial conjunctivitis: unexplained results. Sex Transm Dis 1991, 18:1-4.
242. Bebear C, de Barbeyrac B Genital Chlamydia trachomatis infections. Clin Microbiol Infect 2009, 15:4-10.
243. Taylor BD, Haggerty CL Management of Chlamydia trachomatis genital tract infection: screening and treatment challenges. Infect Drug Resist 2011, 4:19-29.
244. Owusu-Edusei K, Chesson HW, Gift TL, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013, 40:197-201.
245. Lycke E, Löwhagen GB, Hallhagen G, et al. The risk of transmission of genital Chlamydia trachomatis infection is less than that of genital Neisseria gonorrhoeae infection. Sex Transm Dis 1980, 7:6-10.
246. Katz BP, Caine VA, Jones RB Estimation of transmission probabilities for chlamydial infection. Chlamydial Infections 1990, 567-570. Cambridge University Press, Cambridge, UK. W.R. Bowie, H.D. Caldwell, R.P. Jones (Eds.).
247. Quinn TC, Gaydos C, Shepherd M, et al. Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships. JAMA 1996, 276:1737-1742.
248. Althaus CL, Heijne JCM, Low N Towards more robust estimates of the transmissibility of Chlamydia trachomatis. Sex Transm Dis 2012, 39:402-404.
249. Tu W, Ghosh P, Katz BP A stochastic model for assessing Chlamydia trachomatis transmission risk using longitudinally observational data. J R Stat Soc Ser A 2011, 174:975-989.
250. Hook EW, Reichart CA, Upchurch DM, et al. Comparative behavioral epidemiology of gonococcal and chlamydial infections among patients attending a Baltimore, Maryland, sexually transmitted disease clinic. Am J Epidemiol 1992, 136:662-672.
251. Blythe MJ, Katz BP, Orr DP, et al. Historical and clinical factors associated with Chlamydia trachomatis genitourinary infection in female adolescents. J Pediatr 1988, 112:1000-1004.
252. Ramstedt K, Forssman L, Giesecke J, et al. Epidemiologic characteristics of two different populations of women with Chlamydia trachomatis infection and their male partners. Sex Transm Dis 1991, 18:205-210.
253. Oriel JD, Ridgway GL Studies of the epidemiology of chlamydial infection of the human genital tract. Chlamydial Infections 1982, 425-428. Elsevier Biomedical Press, Amsterdam. P.A. Mardh, K.K. Holmes, P. Piot (Eds.).
254. Batteiger BE, Fraiz J, Newhall WJ, et al. Association of recurrent chlamydial infection with gonorrhea. J Infect Dis 1989, 159:661-669.
255. Holmes KK, Handsfield HH, Wang SP, et al. Etiology of nongonococcal urethritis. N Engl J Med 1975, 292:1199-1205.
256. Workowski K In the clinic. Chlamydia and gonorrhea. Ann Intern Med 2013, 158:ITC2-1.
257. Stamm WE, Koutsky LA, Benedetti JK, et al. Chlamydia trachomatis urethral infections in men: prevalence, risk factors, and clinical manifestations. Ann Intern Med 1984, 100:47-51.
258. Cates W, Wasserheit JN Genital chlamydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol 1991, 164:1771-1781.
259. Krieger JN, Verdon M, Siegel N, et al. Risk assessment and laboratory diagnosis of trichomoniasis in men. J Infect Dis 1992, 166:1362-1366.
260. Martin DH Nongonococcal urethritis: new views through the prism of modern molecular biology. Curr Infect Dis Rep 2008, 10:128-132.
261. Manhart LE, Gillespie CW, Lowens MS, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis 2013, 56:934-942.
262. Schwebke J, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens-a randomized clinical trial. Clin Infect Dis 2011, 52:163-170.
263. Stamm WE, Batteiger BE, McCormack WM, et al. A randomized, double-blind study comparing single-dose rifalazil with single-dose azithromycin for the empirical treatment of nongonococcal urethritis in men. Sex Transm Dis 2007, 34:545-552.
264. Lyss SB, Kamb ML, Peterman TA, et al. Chlamydia trachomatis among patients infected with and treated for Neisseria gonorrhoeae in sexually transmitted disease clinics in the United States. Ann Intern Med 2003, 139:178-185.
265. Geisler WM, Wang C, Morrison SG, et al. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis 2008, 35:119-123.
266. Joyner JL, Douglas JM, Foster M, et al. Persistence of Chlamydia trachomatis infection detected by polymerase chain reaction in untreated patients. Sex Transm Dis 2002, 29:196-200.
267. Stamm WE, Cole B Asymptomatic Chlamydia trachomatis urethritis in men. Sex Transm Dis 1986, 13:163-165.
268. Berger RE, Alexander ER, Monda GD, et al. Chlamydia trachomatis as a cause of acute "idiopathic" epididymitis. N Engl J Med 1978, 298:301-304.
269. Trojian TH, Lishnak TS, Heiman D Epididymitis and orchitis: an overview. Am Fam Physician 2009, 79:583-587.
270. Berger RE, Alexander ER, Harnisch JP, et al. Etiology, manifestations and therapy of acute epididymitis: prospective study of 50 cases. J Urol 1979, 121:750-754.
271. Ruijs GJ, Kauer FM, Jager S, et al. Is serology of any use when searching for correlations between Chlamydia trachomatis infection and male infertility?. Fertil Steril 1990, 53:131-136.
272. Shortliffe LMD, Sellers RG, Schachter J The characterization of the nonbacterial prostatitis: search for an etiology. J Urol 1992, 148:1461-1466.
273. Hoentjen F, Rubin DT Infectious proctitis: when to suspect it is not inflammatory bowel disease. Dig Dis Sci 2012, 57:269-273.
274. Quinn TC, Goodell SE, Mkrtichian E, et al. Chlamydia trachomatis proctitis. N Engl J Med 1981, 305:195-200.
275. Stamm WE Chlamydia trachomatis infections of the adult. Sexually Transmitted Diseases 1999, 407-422. McGraw-Hill, New York. 3rd ed. K.K. Holmes, P.A. Mardh, P.F. Sparling (Eds.).
276. Quint KD, Bom RJ, Quint WG, et al. Anal infections with concomitant Chlamydia trachomatis genotypes among men who have sex with men in Amsterdam, the Netherlands. BMC Infect Dis 2011, 11:63.
277. Schachter J, Grossman M, Holt J, et al. Infection with Chlamydia trachomatis: involvement of multiple anatomic sites in neonates. J Infect Dis 1979, 139:232-234.
278. Jones RB, Rabinovitch RA, Katz BP, et al. Recovery of Chlamydia trachomatis from the pharynx and rectum of heterosexual patients at risk for genital infection. Ann Intern Med 1985, 6:757-762.
279. Rahman MU, Hudson AP, Schumacher HR Chlamydia and Reiter's syndrome (reactive arthritis). Rheum Dis Clin North Am 1992, 18:67-79.
280. Keat A, Thomas BJ, Taylor-Robinson D Chlamydial infection in the aetiology of arthritis. Br Med Bull 1983, 39:168-174.
281. Keat A Extragenital Chlamydia trachomatis infection as sexually-acquired reactive arthritis. J Infect 1992, 25(suppl 1):47-49.
282. Sieper J, Braun J, Brandt J, et al. Pathogenetic role of Chlamydia, Yersinia and Borrelia in undifferentiated oligoarthritis. J Rheumatol 1992, 19:1236-1242.
283. Lauhio A, Leirisalo-Repo M, Lähdevirta J, et al. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 1991, 34:6-14.
284. Gerard HC, Branigan PJ, Schumacher HR, et al. Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol 1998, 25:734-742.
285. Bardin T, Enel C, Cornelis F, et al. Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population. Arthritis Rheum 1992, 35:190-194.
286. Carter JD, Hudson AP The evolving story of Chlamydia-induced reactive arthritis. Curr Opin Rheumatol 2010, 22:424-430.
287. Carter JD, Espinoza LR, Inman RD, et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum 2010, 62:1298-1307.
288. Washington AE, Gove S, Schachter J, et al. Oral contraceptives, Chlamydia trachomatis infection, and pelvic inflammatory disease. JAMA 1985, 253:2246-2250.
289. Centers for Disease Control and Prevention CDC Grand Rounds: chlamydia prevention: challenges and strategies for reducing disease burden and sequelae. MMWR Morb Mortal Wkly Rep 2011, 60:370-373.
290. Hillis SD, Nakashima A, Marchbanks PA, et al. Risk factors for recurrent Chlamydia trachomatis infections in women. Am J Obstet Gynecol 1994, 170:801-806.
291. Hillis SD, Owens LM, Marchbanks PA, et al. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol 1997, 176:103-107.
292. Handsfield HH, Jasman LL, Roberts PL, et al. Criteria for selective screening for Chlamydia trachomatis infection in women attending family planning clinics. JAMA 1986, 255:1730-1734.
293. Wolner-Hanssen P, Patton DL, Holmes KK Protective immunity in pigtailed macaques after cervical infection with Chlamydia trachomatis. Sex Transm Dis 1991, 18:21-25.
294. Rahm VA, Gnarpe H, Odlind V Chlamydia trachomatis among sexually active teenage girls: lack of correlation between chlamydial infection, history of the patient and clinical signs of infection. Br J Obstet Gynaecol 1988, 95:916-919.
295. Dean D, Suchland RJ, Stamm WE Evidence for long-term persistence of C. trachomatis by Omp-1 genotyping. J Infect Dis 2000, 182:909-916.
296. Dunlop EMC, Garner A, Darougar S, et al. Colposcopy, biopsy, and cytology results in women with chlamydial cervicitis. Genitourin Med 1989, 65:22-31.
297. Stamm WE, Wagner KF, Amsel R, et al. Causes of the acute urethral syndrome in women. N Engl J Med 1980, 303:409-415.
298. Hare MJ, Taylor-Robinson D, Cooper P Evidence for an association between Chlamydia trachomatis and cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1982, 89:489-492.
299. Schachter J, Hill EC, King EB, et al. Chlamydia trachomatis and cervical neoplasia. JAMA 1982, 248:2134-2138.
300. Naucler P, Chen HC, Persson K, et al. Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J Gen Virol 2007, 88:814-822.
301. Koskela P, Anttila T, Bjorge T, et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000, 85:35-39.
302. Smith JS, Bosetti C, Munoz N, et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004, 111:431-439.
303. Madeleine MM, Anttila T, Schwartz SM, et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer 2007, 120:650-655.
304. Anttila T, Saikku P, Koskela P, et al. Serotypes of C. trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001, 285:47-51.
305. Lehtinen M, Dillner J, Knekt P, et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. BMJ 1996, 312:537-539.
306. Shew ML, Fortenberry JD, Tu W, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med 2006, 160:151-156.
307. Knowlton AE, Brown HM, Richards TS, et al. Chlamydia trachomatis infection causes mitotic spindle pole defects independently from its effects on centrosome amplification. Traffic 2011, 12:854-866.
308. Knowlton AE, Fowler LJ, Patel RK, et al. Chlamydia induces anchorage independence in 3T3 cells and detrimental cytological defects in an infection model. PLoS One 2013, 8:e54022.
309. Laga M, Manoka A, Kivuvu M, et al. Nonulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993, 7:95-102.
310. Centers for Disease Control and Prevention HIV prevention through early detection and treatment of other sexually transmitted diseases-United States. MMWR Morb Mortal Wkly Rep 1998, 47:2-4.
311. Paavonen J, Aine R, Teisala K, et al. Comparison of endometrial biopsy and peritoneal fluid cytologic testing and laparoscopy in the diagnosis of acute pelvic inflammatory disease. Am J Obstet Gynecol 1985, 151:645-650.
312. Cates W, Rolfs RT, Aral SO Sexually transmitted diseases, pelvic inflammatory disease, and infertility: an epidemiologic update. Epidemiol Rev 1990, 12:199-220.
313. Stamm WE, Guinan ME, Johnson C, et al. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med 1984, 310:545-549.
314. Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ 2010, 340:c1642.
315. Herzog S, Althaus C, Heijne J, et al. Timing of progression from Chlamydia trachomatis infection to pelvic inflammatory disease: a mathematical modelling study. BMC Infect Dis 2012, 12:187.
316. Paavonen J Genital Chlamydia trachomatis infections in the female. J Infect 1992, 25(suppl 1):39-45.
317. Svenssen L, Westrom L, Ripa KT, et al. Differences in some clinical and laboratory parameters in acute salpingitis related to culture and serologic findings. Am J Obstet Gynecol 1980, 138:1017-1021.
318. Scholes D, Stergachis A, Heidrich FC, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996, 334:1362-1366.
319. Patton DL, Wölner-Hanssen P, Cosgrove SJ, et al. The effects of Chlamydia trachomatis on the female reproductive tract of the Macaca nemestrina after a single tubal challenge following repeated cervical inoculations. Obstet Gynecol 1990, 76:643-650.
320. Brunham RC, Binns B, Guijon F, et al. Etiology and outcome of acute pelvic inflammatory disease. J Infect Dis 1988, 158:510-517.
321. Weström L, Joesoef R, Reynolds G, et al. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992, 19:185-192.
322. Shepard MK, Jones RB Recovery of Chlamydia trachomatis from endometrial and fallopian tube biopsies in women with infertility of tubal origin. Fertil Steril 1989, 52:232-238.
323. Henry-Suchet J, Catalan F, Loffredo V, et al. Chlamydia trachomatis associated with chronic inflammation in abdominal specimens from women selected for tuboplasty. Fertil Steril 1981, 36:599-605.
324. Brunham RC, Binns F, McDowell J, et al. Chlamydia trachomatis infection in women with ectopic pregnancy. Obstet Gynecol 1986, 67:722-726.
325. Hillis SD, Owens LM, Marchbanks PA, et al. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol 1997, 176:103-107.
326. Witkin SS, Ledger WJ Antibodies to Chlamydia trachomatis in sera of women with recurrent spontaneous abortions. Am J Obstet Gynecol 1992, 167:135-139.
327. McGregor JA, French JI Chlamydia trachomatis infection during pregnancy. Am J Obstet Gynecol 1991, 164:1782-1789.
328. Berman SM, Harrison HR, Boyce WT, et al. Low birth weight, prematurity, and postpartum endometritis: association with prenatal cervical Mycoplasma hominis and Chlamydia trachomatis infections. JAMA 1987, 257:1189-1194.
329. Gravett MG, Nelson HP, DeRouen T, et al. Independent associations of bacterial vaginosis and Chlamydia trachomatis infection with adverse pregnancy outcome. JAMA 1986, 256:1899-1903.
330. Martius J, Krohn MA, Hillier SL, et al. Relationships of vaginal Lactobacillus species, cervical Chlamydia trachomatis, and bacterial vaginosis to preterm birth. Obstet Gynecol 1988, 71:89-95.
331. Ryan GM, Abdella TN, McNeeley SG, et al. Chlamydia trachomatis infection in pregnancy and effect of treatment on outcome. Am J Obstet Gynecol 1990, 162:34-39.
332. Cohen I, Vielle JC, Calkins BM Improved pregnancy outcome following successful treatment of chlamydial infection. JAMA 1990, 263:3160-3163.
333. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med 1995, 333:1737-1742.
334. Meyers JD, Hackman RC, Stamm WE Chlamydia trachomatis infection as a cause of pneumonia after human marrow transplantation. Transplantation 1983, 36:130-134.
335. Bernstein DI, Hubbard T, Wenman WM, et al. Mediastinal and supraclavicular lymphadenitis and pneumonitis due to Chlamydia trachomatis serovars L1 and L2. N Engl J Med 1984, 311:1543-1546.
336. Komaroff AL, Aronson MD, Schachter J Chlamydia trachomatis infection in adults with community-acquired pneumonia. JAMA 1981, 245:1319-1322.
337. Myhre EB, Mardh PA Chlamydia trachomatis infection in a patient with meningoencephalitis. N Engl J Med 1981, 304:910-911.
338. Grayston JT, Mordhorst CH, Wang SP Childhood myocarditis associated with Chlamydia trachomatis infection. JAMA 1981, 246:2823-2837.
339. van der Bel-Kahn JM, Watanakunakorn C, Menefee MG, et al. Chlamydia trachomatis endocarditis. Am Heart J 1978, 95:627-636.
340. Suchland RJ, Geisler WM, Stamm WE Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother 2003, 47:636-642.
341. Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J Med 1992, 327:921-925.
342. Hillis SD, Coles B, Litchfield B, et al. Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence 1 month after treatment in women: a use-effectiveness study in public health settings. Sex Transm Dis 1998, 25:5-11.
343. Fortenberry JD, Brizendine EJ, Katz BP, et al. Subsequent STDs among adolescent women with C. trachomatis, N. gonorrhoeae or T. vaginalis. Sex Transm Dis 1999, 26:26-32.
344. Lau C-Y, Qureshi AK Azithromycin versus doxycycline for genital chlamydial infections. Sex Transm Dis 2002, 29:497-502.
345. Golden MR, Whittington WLH, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005, 352:676-685.
346. Stamm WE, Hicks CB, Martin DH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men: a randomized double-blind study. JAMA 1995, 274:545-549.
347. Geisler WM, Koltun WD, Abdelsayed N, et al. Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital Chlamydia trachomatis infection: a randomized, double-blind, double-dummy, active-controlled, multicenter trial. Clin Infect Dis 2012, 55:82-88.
348. Stamm WE, Geisler WM, Suchland RJ Assessment of antimicrobial resistance in C. trachomatis strains associated with treatment failure or same strain recurrence. Chlamydial Infections, Proceedings of the Tenth International Symposium on Human Chlamydial Infections 2002, International Chlamydial Symposium, San Francisco. J. Schachter, G. Christiansen, I.N. Clarke (Eds.).
349. Magat AH, Alger LS, Nagey DA, et al. Double-blind randomized study comparing amoxicillin and erythromycin for the treatment of Chlamydia trachomatis in pregnancy. Obstet Gynecol 1993, 81:745-749.
350. Crombleholme WR, Schachter J, Grossman M, et al. Amoxicillin therapy for Chlamydia trachomatis in pregnancy. Obstet Gynecol 1990, 75:752-756.
351. Bowie WR, Yu JS, Jones HD Partial efficacy of clindamycin against Chlamydia trachomatis in men with nongonococcal urethritis. Sex Transm Dis 1986, 13:76-80.
352. Alger LS, Lovchik JC Comparative efficacy of clindamycin versus erythromycin in eradication of antenatal Chlamydia trachomatis. Am J Obstet Gynecol 1991, 165:375-381.
353. Campbell WF, Dodson MG Clindamycin therapy for Chlamydia trachomatis in women. Am J Obstet Gynecol 1990, 162:343-347.
354. Hathorn E, Opie C, Goold P What is the appropriate treatment for the management of rectal Chlamydia trachomatis in men and women?. Sex Transm Infect 2012, 88:352-354.
355. McLean CA, Stoner BP, Workowski KA Treatment of lymphogranuloma venereum. Clin Infect Dis 2007, 44(suppl 3):S147-S152.
356. Viswalingam ND, Daroughar S, Yearsley P Oral doxycycline in the treatment of adult chlamydial ophthalmia. Br J Ophthalmol 1986, 70:301-304.
357. Darville T Chlamydia trachomatis infections in neonates and young children. Semin Pediatr Infect Dis 2005, 16:235-244.
358. Shariat H, Young M, Abedin M An interesting case presentation: a possible new route for perinatal acquisition of Chlamydia. J Perinatol 1992, 12:300-302.
359. Hammerschlag MR Chlamydial and gonococcal infections in infants and children. Clin Infect Dis 2011, 53(suppl 3):S99-102.
360. Chandler JW, Alexander ER, Pheiffer TA, et al. Ophthalmia neonatorum associated with maternal chlamydial infections. Trans Am Acad Ophthalmol Otolaryngol 1977, 83:302-308.
361. Schachter J, Dawson CR Human Chlamydial Infections 1978, PSG Publishing, Littleton, MA.
362. Bell TA, Stamm WE, Wang SP, et al. Chronic Chlamydia trachomatis infections in infants. JAMA 1992, 267:400-402.
363. Persson K, Rönnerstam R, Svanberg L, et al. Neonatal chlamydial eye infection: an epidemiological and clinical study. Br J Ophthalmol 1983, 67:700-704.
364. Hammerschlag MR, Cummings C, Roblin PM, et al. Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. N Engl J Med 1989, 320:769-772.
365. Schachter J, Grossman M, Sweet RL, et al. Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA 1986, 255:3374-3377.
366. Tipple MA, Beem MO, Saxon EM Clinical characteristics of the afebrile pneumonia associated with Chlamydia trachomatis infection in infants less than 6 months of age. Pediatrics 1979, 63:192-197.
367. Beem MO, Saxon EM Respiratory tract colonization and a distinctive pneumonia syndrome in infants infected with Chlamydia trachomatis. N Engl J Med 1977, 296:306-310.
368. Harrison HR, English MG, Lee CK, et al. Chlamydia trachomatis infant pneumonitis: comparison with matched controls and other infant pneumonitis. N Engl J Med 1978, 288:702-708.
369. Wheeler WB, Kurachek SC, Lobas JG, et al. Acute hypoxemic respiratory failure caused by Chlamydia trachomatis and diagnosed by flexible bronchoscopy. Am Rev Respir Dis 1990, 142:471-473.
370. Broadbent R, O'Leary L Chlamydial infections in young infants-a cause for concern. N Z Med J 1988, 101:44-45.
371. Brasfield DM, Stagno S, Whitley RJ, et al. Infant pneumonitis associated with cytomegalovirus, Chlamydia, Pneumocystis, and Ureaplasma: follow-up. Pediatrics 1987, 79:76-83.
372. Weiss SG, Newcomb RW, Beem MO Pulmonary assessment of children after chlamydial pneumonia of infancy. J Pediatr 1986, 108:659-664.
373. Heggie AD, Jaffe AC, Stuart LA, et al. Topical sulfacetamide vs oral erythromycin for neonatal chlamydial conjunctivitis. Am J Dis Child 1985, 139:564-566.
374. Crombleholme WR, Schachter J, Grossman M, et al. Amoxicillin therapy for Chlamydia trachomatis in pregnancy. Obstet Gynecol 1990, 75:752-756.
375. Schachter J, Sweet RL, Grossman M, et al. Experience with the routine use of erythromycin for chlamydial infections in pregnancy. N Engl J Med 1986, 314:276-279.
376. Oh MK, Cloud GA, Baker SL, et al. Chlamydial infection and sexual behavior in young pregnant teenagers. Sex Transm Dis 1993, 20:45-50.
377. White JA Manifestations and management of lymphogranuloma venereum. Curr Opin Infect Dis 2009, 22:57-66.
378. Mabey D, Peeling RW Lymphogranuloma venereum. Sex Transm Infect 2002, 78:90-92.
379. Perine PL, Osoba AO Lymphogranuloma venereum. Sexually Transmitted Diseases 1990, 195-204. McGraw-Hill, New York. 2nd ed. K.K. Holmes, P.A. Mardh, P.F. Sparling (Eds.).
380. Perine PL, Stamm WE Lymphogranuloma venereum. Sexually Transmitted Diseases 1999, 423-432. McGraw-Hill, New York. 3rd ed. K.K. Holmes, P.F. Sparing (Eds.).
381. D'Aunoy R, von Haam E General reviews: venereal lymphogranuloma. Arch Pathol 1939, 27:1032-1082.
382. Levine JS, Smith PD, Brugge WR Chronic proctitis in male homosexuals due to lymphogranuloma venereum. Gastroenterology 1980, 79:563-565.
383. Schachter J, Moncada J Lymphogranuloma venereum: how to turn an endemic disease into an outbreak of a new disease? Start looking. Sex Transm Dis 2005, 32:331-332.
384. Annamunthodo H Rectal lymphogranuloma venereum in Jamaica. Ann R Coll Surg Engl 1961, 28:141-159.
385. Spaargaren J, Schachter J, Moncada J, et al. Slow epidemic of lymphogranuloma venereum L2b strain. Emerg Infect Dis 2005, 11:1787-1788.
386. Herring A, Richens J Lymphogranuloma venereum. Sex Transm Infect 2006, 82(suppl 4):iv23-iv25.
387. Coutts WE Lymphogranuloma venereum: a general review. Bull World Health Organ 1950, 2:545-562.
388. Wilkinson D, Tholandi M, Ramjee G, et al. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2002, 2:613-617.
389. Gottlieb SL, Xu F, Brunham RC Screening and treating Chlamydia trachomatis genital infection to prevent pelvic inflammatory disease: interpretation of findings from randomized controlled trials. Sex Transm Dis 2013, 40:97-102.
390. U.S.Preventive Services Task Force Screening for chlamydial infection: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007, 147:128-134.
391. Heijne JCM, Tao G, Kent CK, Low N Uptake of regular Chlamydia testing by U.S. women: a longitudinal study. Am J Prevent Med 2010, 39:243-250.
392. van den Broek IV, van Bergen JE, Brouwers EE, et al. Effectiveness of yearly, register based screening for Chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation. BMJ 2012, 345:e4316.
393. Burstein GR, Gaydos CA, Diener-West M, et al. Incident Chlamydia trachomatis infection among inner-city adolescents. JAMA 1998, 280:521-526.
394. Hoover KW, Tao G, Nye MB, Body BA Suboptimal adherence to repeat testing recommendations for men and women with positive Chlamydia tests in the United States, 2008-2010. Clin Infect Dis 2013, 56:51-57.
395. Xu F, Stoner BP, Taylor SN, et al. Use of home-obtained vaginal swabs to facilitate rescreening for Chlamydia trachomatis infections: two randomized controlled trials. Obstet Gynecol 2011, 118:231-239.
396. Guy R, Hocking J, Low N, et al. Interventions to increase rescreening for repeat chlamydial infection. Sex Transm Dis 2012, 39:136-146.
397. Gaydos CA, Howell MR, Pare B, et al. Chlamydia trachomatis infections in female military recruits. N Engl J Med 1998, 339:739-744.
398. Rietmeijer CA, Yamaguchi KJ, Ortiz CG, et al. Feasibility and yield of screening urine for Chlamydia trachomatis by polymerase chain reaction among high-risk male youth in field-based and other nonclinic settings. Sex Transm Dis 1997, 24:429-435.
399. Cohen DA, Nsuami M, Etame RB, et al. A school-based Chlamydia control program using DNA amplification technology. Pediatrics 1998, 101:E1.
400. Rekart ML, Gilbert M, Meza R, et al. Chlamydia public health programs and the epidemiology of pelvic inflammatory disease and ectopic pregnancy. J Infect Dis 2013, 207:30-38.
401. Brunham RC, Rekart ML The arrested immunity hypothesis and the epidemiology of chlamydia control. Sex Transm Dis 2008, 35:53-54.
402. Katz BP, Danos CS, Quinn TS, et al. Efficiency and cost effectiveness of field follow-up for patients with Chlamydia trachomatis infection in a sexually transmitted diseases clinic. Sex Transm Dis 1988, 15:11-16.
403. Ripa T Epidemiologic control of genital Chlamydia tra-chomatis infections. Scand J Infect Dis 1990, 69(suppl):157-167.
404. Golden MR, Whittington WLH, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005, 352:676-685.
405. Bhosai SJ, Bailey RL, Gaynor BD, Lietman TM Trachoma: an update on prevention, diagnosis, and treatment. Curr Opin Ophthalmol 2012, 23:288-295.
406. Centers for Disease Control and Prevention Sexually transmitted diseases surveillance 2011 2012, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.
407. Datta SD, Torrone E, Kruszon-Moran D, et al. Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999-2008. Sex Transm Dis 2012, 39:92-96.
408. Batteiger BE Chlamydia infection and epidemiology. Intracellular Pathogens I: Chlamydiales 2012, 1-26. ASM Press, Washington, DC. M. Tan, P.M. Bavoil (Eds.).
409. Moulder JW Interaction of chlamydiae and host cells in vitro. Microbiol Rev 1991, 55:143-190.
410. Fields KA Protein secretion and Chlamydia pathogenesis. Intracellular Pathogens I: Chlamydiales 2012, 192-216. ASM Press, Washington, DC. M. Tan, P.M. Bavoil (Eds.).
411. Hackstadt T Initial interactions of chlamydiae with the host cell. Intracellular Pathogens I: Chlamydiales 2012, 126-148. ASM Press, Washington, DC. M. Tan, P.M. Bavoil (Eds.).
412. Kokes M, Valdivia RH Cell biology of the chlamydial inclusion. Intracellular Pathogens I: Chlamydiales 2012, 170-188. ASM Press, Washington, DC. M. Tan, P.M. Bavoil (Eds.).
413. Tan M Temporal gene regulation during the chlamydial development cycle. Intracellular Pathogens I: Chlamydiales 2012, 149-169. ASM Press, Washington, DC. M. Tan, P.M. Bavoil (Eds.).
414. Chen AL, Johnson KA, Lee JK, et al. CPAF: a chlamydial protease in search of an authentic substrate. PLoS Pathog 2012, 8:e1002842.
415. Wyrick PB Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis 2010, 201(suppl 2):S88-S95.
416. Wang SP, Grayston JT Microimmunofluorescence antibody responses in Chlamydia trachomatis infection, a review. Chlamydial Infections 1982, 301-316. Elsevier Biomedical Press, Amsterdam. P.A. Mardh, K.K. Holmes, J.D. Oriel (Eds.).
417. Martin-Iguacel R, Llibre JM, Nielsen H, et al. Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialised countries. Eur J Clin Microbiol Infect Dis 2010, 29:917-925.
418. Batteiger Byron E, Tu W, Ofner S, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010, 201:42-51.
419. Caldwell HD, Wood H, Crane D, et al. Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J Clin Invest 2003, 111:1757-1769.
420. Harris SR, Clarke IN, Seth-Smith HM, et al. Whole-genome analysis of diverse Chlamydia trachomatis strains identifies phylogenetic relationships masked by current clinical typing. Nat Genet 2012, 44:413-419.
421. Wang Y, Kahane S, Cutcliffe LT, et al. Development of a transformation system for Chlamydia trachomatis: restoration of glycogen biosynthesis by acquisition of a plasmid shuttle vector. PLoS Pathog 2011, 7:e1002258.
422. Kari L, Goheen MM, Randall LB, et al. Generation of targeted Chlamydia trachomatis null mutants. Proc Natl Acad Sci U S A 2011, 108:7189-7193.
423. Nguyen BD, Valdivia RH Virulence determinants in the obligate intracellular pathogen Chlamydia trachomatis revealed by forward genetic approaches. Proc Natl Acad Sci U S A 2012, 109:1263-1268.
424. Brunham RC, Paavonen J, Stevens CE, et al. Mucopurulent cervicitis: the ignored counterpart in women of urethritis in men. N Engl J Med 1984, 311:1-6.
425. Darville T, Hiltke TJ Pathogenesis of genital tract disease due to Chlamydia trachomatis. J Infect Dis 2010, 201(suppl 2):S114-S125.
426. Stephens RS The cellular paradigm of chlamydial pathogenesis. Trends Microbiol 2003, 11:44-51.
427. Darville T, O'Neill JM, Andrews CW, et al. Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J Immunol 2003, 171:6187-6197.
428. Molano M, Meijer CJLM, Weiderpass E, et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis 2005, 191:907-916.
429. O'Connell CM, Ingalls RR, Andrews CW, et al. Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease. J Immunol 2007, 179:4027-4034.
430. Batteiger BE, Xu F, Johnson RE, Rekart ML Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. J Infect Dis 2010, 201:S178-S189.
431. Grayston JT, Wang SP, Yeh LJ, et al. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis 1985, 7:717-725.
432. Brunham RC, Pourbohloul B, Mak S, et al. The unexpected impact of a Chlamydia trachomatis infection control program on susceptiblity to reinfection. J Infect Dis 2005, 195:1836-1844.
433. Geisler WM, Lensing SY, Press CG, Hook EW Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection. J Infect Dis 2013, 207:1850-1856.
434. Geisler WM Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies. J Infect Dis 2010, 201(suppl 2):S104-S113.
435. Hu VH, Harding-Esch EM, Burton MJ, et al. Epidemiology and control of trachoma: systematic review. Trop Med Int Health 2010, 15:673-691.
436. Stamm WE Chlamydia trachomatis: the persistent pathogen: Thomas Parran Award Lecture. Sex Transm Dis 2001, 28:684-689.
437. Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010, 59:1-110.
438. Harkins AL, Munson E Molecular diagnosis of sexually transmitted Chlamydia trachomatis in the United States. ISRN Obstet Gynecol 2011, 2011:279149.
439. Schachter J, Chernesky MA, Willis DE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis 2005, 32:725-728.
440. Cook RL, Hutchison SL, Ostergaard L, et al. Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005, 142:914-925.
441. Unemo M, Clarke IN The Swedish new variant of Chlamydia trachomatis. Curr Opin Infect Dis 2011, 24:62-69.
442. Scidmore MA Cultivation and laboratory maintenance of Chlamydia trachomatis. Curr Protoc Microbiol 2005.
443. Gaydos CA, Van Der Pol B, Jett-Goheen M, et al. Performance of the Cepheid CT/NG Xpert rapid PCR test for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol 2013, 51:1666-1672.
444. West S Trachoma and antibiotic use: the 'A' in SAFE. Expert Rev Anti Infect Ther 2012, 10:75-83.
445. Holmes KK, Handsfield HH, Wang SP, et al. Etiology of nongonococcal urethritis. N Engl J Med 1975, 292:1199-1205.
446. Berger RE, Alexander ER, Monda GD, et al. Chlamydia trachomatis as a cause of acute "idiopathic" epididymitis. N Engl J Med 1978, 298:301-304.
447. Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ 2010, 340:c1642.
448. Scholes D, Stergachis A, Heidrich FC, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996, 334:1362-1366.
449. Weström L, Joesoef R, Reynolds G, et al. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992, 19:185-192.
450. McLean CA, Stoner BP, Workowski KA Treatment of lymphogranuloma venereum. Clin Infect Dis 2007, 44(suppl 3):S147-S152.
451. Hammerschlag MR Chlamydial and gonococcal infections in infants and children. Clin Infect Dis 2011, 53(suppl 3):S99-S102.
452. Gottlieb SL, Xu F, Brunham RC Screening and treating Chlamydia trachomatis genital infection to prevent pelvic inflammatory disease: interpretation of findings from randomized controlled trials. Sex Transm Dis 2013, 40:97-102.
453. U.S.Preventive Services Task Force Screening for chlamydial infection: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007, 147:128-134.
454. Rekart ML, Gilbert M, Meza R, et al. Chlamydia public health programs and the epidemiology of pelvic inflammatory disease and ectopic pregnancy. J Infect Dis 2013, 207:30-38.
455. Golden MR, Whittington WLH, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005, 352:676-685.